April 9, 2019 : DCMS #444

TOP STORIES — Diabetes News and Research

Comparison of the Effects of GLP1-RA and SGLT2i

Does Metformin Reduce Risk Of Venous Thromboembolism?

Is Metformin Therapy Safe For Use In Stage 3 Chronic Kidney Disease?

EXCLUSIVE INTERVIEW — Candid Video Interviews with Top Practitioners

Sheri Colberg on Exercise and Low Carb Diets for People with Diabetes

MOST POPULAR ARTICLES OF THE MONTH

#1 Low Carb Or Low Fat Diet To Lose Weight?

#2 Effects of Metformin Go Beyond the Treatment of Type 2 Diabetes

#3 Metformin For People Who Do Not Have Diabetes?

Last week our medical editor, Joy Pape, stirred up a little excitement with her feature on the use of metformin in patients with pre-diabetes and even those who only had a family history of diabetes.

This week Ghazal Blair, our LECOM School of Pharmacy Pharm.D. Candidate, finished off her rotation with two more articles on why metformin may be a great choice for all patients as an all purpose fix for multiple primary pathophysiologic abnormalities. 

Dave Joffe

Editor-in-chief

WaveForm Technologies Inc., a subsidiary of AgaMatrix Holdings LLC and A. Menarini Diagnostics S.r.l., announced a partnership to commercialize the WaveForm Technologies Continuous Glucose Monitor (CGM). This system, according to the studies, actually works and is set to launch in Europe later this year, followed by a domestic launch upon FDA approval.

GLP1-RA and SGLT2i reduce atherosclerotic major cardiovascular events (MACE) to a similar degree in patients with established ASCVD.

Drug said to be possible fix for multiple primary pathophysiologic abnormalities.

Metformin may help lower the risk of cardiovascular events and death in patients with moderate to severe renal function.

Sheri R. Colberg, PhD, FACSM is Professor Emerita of Exercise Science from Old Dominion University and an internationally recognized authority on diabetes and exercise. She is the author of 12 books, 27 book chapters, and over 400 articles. The author of “Exercise and Diabetes: A Clinician’s Guide to Prescribing Physical Activity,” published by ADA in 2013, she is also the lead author on a new ADA position statement on physical activity and diabetes published last fall. In 2016, she received the ADA Outstanding Educator in Diabetes Award.

Study provides some answers to ongoing debate about which diet causes most weight loss.

Metformin proposes therapeutic benefit for HFpEF treatment.

We asked the DIC advisory board to comment on the use of metformin in patients who do not have diabetes:

Your patients may have asked about it or, if not yet, they most likely will. What is your comment on whether you recommend metformin for people who do not have diabetes? If you do not, how do you respond to patients who ask about it? If you do, what do you tell your patients? And what do you say to your patients when their other health care providers tell them this is a diabetes drug and they should only be taking it if they have diabetes?

Here’s how they responded.